# A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

> **NCT01033487** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- Lung Diseases
- Respiratory Tract Diseases
- Chronic Obstructive Airway Disease
- COPD

## Interventions

- **DRUG:** placebo
- **DRUG:** active comparator
- **DRUG:** Low Dose PF-03635659
- **DRUG:** Mid Dose PF-03635659
- **DRUG:** High Dose PF-03635659

## Key facts

- **NCT ID:** NCT01033487
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033487, "A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01033487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*